Revive Therapeutics (RVV.C) blasts off, up 68% after FDA Phase 3 COVID-19 approval
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3… Read More »Revive Therapeutics (RVV.C) blasts off, up 68% after FDA Phase 3 COVID-19 approval




